Nephrosant
Latest round
- Series A
Last raised
- Mar 2021
Total raised
- $16M
Investors
- 2
About Nephrosant
, a kidney health spin out of UC San Francisco, operates as a biotechnology company. In March 2021, Nephrosant, Inc. The company develops and provides QiSant, a kidney transplant rejection test to help the prevention, diagnosis, and treatment of kidney injuries for post-transplant patients. The company also provides a needle-free urine test that helps to determine if a patient's body is rejecting a transplanted kidney.
Who invested in Nephrosant
2 investors across 2 rounds
See all investors in Nephrosant
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Nephrosant
Who invested in Nephrosant?
Nephrosant has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Nephrosant raised?
Nephrosant has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Nephrosant last raise money?
Nephrosant's most recent round on record is a Series A, in Mar 2021.
What does Nephrosant do?
, a kidney health spin out of UC San Francisco, operates as a biotechnology company.
Where is Nephrosant headquartered?
Nephrosant is headquartered in Brisbane, US.
Which VCs invest in companies like Nephrosant?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Nephrosant's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Nephrosant? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.